|24th September 2020||Louis Manzo||8,299||Exercise of derivative||$3.70||$30,706.30|
|27th July 2020||Linda Marban||41,497||Exercise of derivative||$3.70||$153,538.90|
|27th July 2020||Linda Marban||15,652||Payment by withholding||$9.81||$153,546.12|
|17th December 2019||Louis Manzo||20,391||Grant/award etc.||$0.00|
|17th December 2019||David B Musket||20,391||Grant/award etc.||$0.00|
|17th December 2019||Frank Litvack||20,391||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.